Information about the medical care and treatment of infants, children and adolescents living with HIV. Paediatric HIV treatment guidelines are different to those for adults.

HIV treatment for children and young people: latest news

HIV treatment for children and young people resources

  • HIV treatment

    HIV treatment is very effective in children with HIV, making it a long-term, manageable condition. Babies, children and adolescents – like everyone else living with HIV – are...

    From: Booklets

    Information level Level 2
  • HIV & children

    This booklet provides information about treatment and care for children living with HIV. ...

    From: Booklets

    Information level Level 2

HIV treatment for children and young people features

HIV treatment for children and young people news from aidsmap

More news

HIV treatment for children and young people news selected from other sources

  • Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

    "Public health (officials) should definitely be aware of the implications of drug resistance mutations conferring resistance to tenofovir and/or lamivudine on the activity, efficacy and durability of DTG in such a country, knowing that at present, individual- level HIV drug resistance testing in low and middle income countries (LMICs) is rare and that data are lacking on DTG use in settings with limited or no viral load monitoring."

    07 July 2019 | Medscape (free registration required)
  • Biktarvy Approved to Treat Pediatric Patients With HIV-1

    he Food and Drug Administration (FDA) has approved updated labeling for Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide; Gilead) to include treatment of both adult and pediatric patients weighing at least 25kg with HIV-1 who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy. Previously, the combination therapy had only been approved for adults.

    20 June 2019 | Monthly Prescribing Reference
  • U.S. Revises Pediatric HIV Treatment Guidelines

    Changes include new information about risks associated with Tivicay during pregnancy and a removal of older drugs owing to toxicities.

    23 April 2019 | Poz
  • Hepatic steatosis common in young adults with life-long HIV

    Thirty-three percent of young adults with HIV since birth or early childhood have hepatic steatosis, a prevalence comparable to older adults with HIV and “significantly higher” than HIV-negative controls, according to research published in The Journal of Infectious Diseases

    26 March 2019 | Healio
  • Weight Monitoring Key to Pediatric ART Dosing in Resource-Limited Countries

    Study findings in a short communication published in HIV Medicine revealed that a large percentage of children living with HIV were prescribed inappropriate doses of antiretroviral therapy (ART) at a pediatric outpatient clinic at Harare Central Hospital in Zimbabwe.

    27 February 2019 | Infectious Disease Advisor
  • Efavirenz and psychological performance in children living with HIV

    Efavirenz remains a clinically effective and relevant antiretroviral drug for people living with HIV – but adverse side effects need to be screened for and monitored in children.

    15 February 2019 | AVERT
  • UNAIDS, UNICEF and WHO urge countries in western and central Africa to step up the pace in the response to HIV for children and adolescents

    At a high-level meeting in Dakar, Senegal, UNAIDS, the United Nations Children’s Fund (UNICEF) and the World Health Organization (WHO) urged countries in western and central Africa to do more to stop new HIV infections among children and adolescents and increase HIV testing and treatment coverage. 

    16 January 2019 | UNAIDS press release
  • Children, HIV and AIDS: The world today and in 2030

    The world pledged to end AIDS by 2030. While we have seen remarkable progress in the past decade among children aged 0-9 years, adolescents have been left behind in HIV prevention efforts. A staggering 360,000 adolescents are projected to die of AIDS-related diseases between 2018 and 2030 without additional investment in HIV prevention, testing and treatment programs.

    30 November 2018 | UNICEF
  • Pharmaceutical corporations are failing children with HIV

    One year ago, pharmaceutical corporations committed to improving access to paediatric versions of HIV drugs for children, but very little progress has been made. MSF urges pharmaceutical corporations including Viiv and Merck to immediately register paediatric ARVs and improve access for kids.

    30 November 2018 | Médecins Sans Frontières (MSF)
  • MSF: Pharmaceutical corporations failing children with HIV

    Developing countries are struggling to provide HIV-positive children with World Health Organization (WHO)-recommended treatments because pediatric versions of HIV medicines don’t exist, are priced out of reach, or haven’t been registered in all countries that need them, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) ahead of a Vatican City meeting of HIV stakeholders on scaling up diagnosis and treatment for children.

    29 November 2018 | Doctors Without Borders
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.